ASND•Ascendis Pharma said Transcon CNP could receive 10 years of orphan market exclusivity upon European Commission adoption, with a final decision on its marketing application expected in Q4 2026.
The European Medicines Agency’s Committee for Orphan Medicinal Products adopted a positive opinion on orphan designation for Transcon CNP (navepegritide). Upon European Commission adoption, the designation provides 10 years of orphan market exclusivity. Ascendis expects a final EC decision on its marketing application in Q4 2026; if authorized, the company expects its first EU launch, in Germany, in Q1 2027.
